GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Clinical trial NCT04060342 · TERMINATED

Trial details

NCT number: NCT04060342
Sponsor: GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Adenocarcinoma Esophageal Adenocarcinoma Esophageal Squamous Cell Carcinoma Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Triple Negative Breast Cancer Castration-resistant Prostate Cancer Microsatellite Stable Colorectal Cancer Non-small Cell Lung Cancer Small-cell Lung Cancer Head and Neck Squamous Cell Carcinoma Urothelial Carcinoma

Start date: 2019-08-13
Primary completion: 2022-04-11
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.